menu search

ADMA / ADMA Biologics: An Emerging Growth Play

ADMA Biologics: An Emerging Growth Play
Today, we take a deeper look at ADMA Biologics, Inc., whose stock has doubled over the past year thanks to robust sales growth. The company continues to expand its plasma collection network, is delivering impressive growth and is pursuing margin enhancing initiatives. An investment analysis follows in the paragraphs below. Read More
Posted: Jun 15 2023, 14:15
Author Name: Seeking Alpha
Views: 081221

ADMA News  

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

By Zacks Investment Research
November 2, 2023

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Adma Biologics (ADMA) closed the most recent trading day at $3.45, moving -1.99% from the previous trading session. more_horizontal

Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note

By Zacks Investment Research
October 27, 2023

Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note

Adma Biologics (ADMA) closed at $3.31 in the latest trading session, marking a +0.91% move from the prior day. more_horizontal

Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts

By Zacks Investment Research
October 17, 2023

Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts

In the most recent trading session, Adma Biologics (ADMA) closed at $3.44, indicating a +1.78% shift from the previous trading day. more_horizontal

Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why

By Zacks Investment Research
October 9, 2023

Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $3.34, denoting a -0.3% change from the preceding trading day. more_horizontal

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

By Zacks Investment Research
September 13, 2023

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about more_horizontal

Why Shares of ADMA Biologics Are Climbing Thursday

By The Motley Fool
August 10, 2023

Why Shares of ADMA Biologics Are Climbing Thursday

ADMA grew revenue and trimmed its losses compared to the same quarter a year ago. The company increased revenue guidance for 2023, 2024, and 2025. more_horizontal

ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?

By Zacks Investment Research
July 28, 2023

ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?

On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs. more_horizontal


Search within

Pages Search Results: